PATH
Menu

This literature review details the key findings on the feasibility and acceptability of home delivery of depo-subQ provera 104™ in the Uniject™ injection system  (depo-subQ in Uniject). The review focused on self-injection and looked specifically at subcutaneous depot medroxyprogesterone acetate (DMPA) compared to the intramuscular formulation; considerations for home administration of injectable contraception, particularly in low-resource settings; and identified research needs for home administration, including self-injection, of depo-subQ in Uniject. A six-page briefing summary of this review is also available.

Author(s): Keith BM

Corporate author(s): PATH

Publication date: July 2011

Available materials

English

Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.

Region: Global

See also:

Health technologiesSafe injection

Reproductive healthFamily planning

Health technologiesWoman-initiated protection

For more information…

Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA